Comparing the current results to its competitors, Amylyx Pharmaceuticals Inc reported Revenue decrease in the 1 quarter 2026 year on year by 0 %, despite the revenue increase by the most of its competitors of 26.62 %, recorded in the same quarter.
Amylyx Pharmaceuticals Inc , despite income growth by most of its competitors recorded a net loss, despite income increase by most of its competitors of 79.38 %
Amylyx Pharmaceuticals Inc 's Comment on Competition and Industry Peers
The company faces potential competition from major and specialty pharmaceutical and biotechnology companies, academic research institutions, governmental agencies, compounding pharmacies, and public and private research institutions. Competitors may possess greater financial resources and expertise in research and development, preclinical testing, clinical trials, manufacturing, and marketing. Future collaborations and mergers could consolidate resources among fewer competitors. Some competitors may obtain regulatory approvals more quickly, establishing market positions prior to the company's entry. Additionally, competitors vie for qualified scientific and management personnel, clinical trial sites and patient populations, and complementary technologies.
May 9, 2024
Neurodegenerative diseases, such as Alzheimer s disease, Parkinson s disease, and amyotrophic lateral sclerosis (ALS), have devastating impacts on patients and their families. Recognizing the urgent need for effective treatments, Amylyx Pharmaceuticals, a leading biopharmaceutical company based in Cambridge, Massachusetts, has recently shared their first quarter 2024 financial results. This article aims to delve into the strategic decisions taken by Amylyx Pharmaceuticals, their focus on key clinical and preclinical programs, and their commitment to ending the suffering caused by neurodegenerative diseases.Amylyx Pharmaceuticals Swift Action:In the first quarter of 2024, Amylyx Pharmaceuticals implemented m...
March 8, 2024
Amylyx Pharmaceuticals Phase 3 Trial of AMX0035 in ALS Fails to Meet Primary EndpointAmylyx Pharmaceuticals, a biopharmaceutical company based in Cambridge, Massachusetts, recently announced the topline results from its global Phase 3 clinical trial of AMX0035 in patients with amyotrophic lateral sclerosis (ALS). Unfortunately, the trial did not meet its primary endpoint of reaching statistical significance.ALS, also known as Lou Gehrig s disease, is a neurodegenerative condition that affects nerve cells in the brain and spinal cord, leading to the progressive loss of muscle control and eventual paralysis. There is currently no cure for ALS, and the available treatment options only offer limited relief from...
Publicly Traded Peers of Amylyx Pharmaceuticals Inc
Biovie Inc Share Performance
+41.77%
One Year
Biovie Inc
Profile
Biovie Inc is a biotechnology company that aims to develop advanced therapeutic solutions for various diseases. They have a unique business model that focuses on research and development of innovative drugs, strategic partnerships and collaborations with other organizations, along with potential commercialization of their products to generate revenue. Their goal is to create groundbreaking medical treatments that improve the quality of life for patients.
Edesa Biotech Inc's business model focuses on the development and commercialization of innovative therapeutics in the field of dermatology and gastrointestinal diseases.
Gain Therapeutics inc's business model revolves around using cutting-edge technology and innovative approaches to identify and develop small molecules that can effectively target and treat rare genetic diseases, such as lysosomal storage disorders and CNS-related disorders. They aim to leverage their expertise in computational drug design and protein structure analysis to discover potential drug candidates, which can then be developed and commercialized for therapeutic purposes.
Galapagos Nv's business model is centered around the development and commercialization of innovative medicines. They leverage their expertise in drug discovery and development to collaborate with partners in the healthcare industry, focusing on the advancement of novel therapies to address unmet medical needs.
Gossamer Bio Inc operates with a business model focused on the development and commercialization of novel therapies for patients with complex diseases. They leverage extensive scientific expertise and strategic partnerships to identify and advance a diverse pipeline of innovative medicines. Their goal is to deliver transformative therapies that address significant unmet medical needs and improve patient outcomes.
Sources:
Amylyx Pharmaceuticals Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Amylyx Pharmaceuticals Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
